The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease

Published:2017-12 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Cazanave Sophie,Podtelezhnikov Alexei,Jensen Kristian,Seneshaw Mulugeta,Kumar Divya P.,Min Hae-Ki,Santhekadur Prasanna K.,Banini Bubu,Mauro Adolfo Gabriele,M. Oseini Abdul,Vincent Robert,Tanis Keith Q.,Webber Andrea L.,Wang Liangsu,Bedossa Pierre,Mirshahi Faridoddin,Sanyal Arun J.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-17370-6.pdf

Reference52 articles.

1. Loomba, R. & Sanyal, A. J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686–690 (2013).

2. Pais, R. et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology 59, 550–556 (2013).

3. Schattenberg, J. M. & Schuppan, D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr. Opin. Lipidol. 22, 479–88 (2011).

4. Pacana, T. & Sanyal, A. J. Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep. 7, 28 (2015).

5. Peverill, W., Powell, L. W. & Skoien, R. Evolving concepts in the pathogenesis of NASH: Beyond steatosis and inflammation. International Journal of Molecular Sciences 15, 8591–8638 (2014).

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Honey vesicle-like nanoparticles protect aged liver from non-alcoholic steatohepatitis;Acta Pharmaceutica Sinica B;2024-08

2. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives;Molecular Oncology;2024-06-14

3. Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: primary and secondary gene responses with links to disease progression;Toxicological Sciences;2024-05-06

4. Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression;2024-02-20

5. Integrated transcriptomic landscape of the effect of anti‐steatotic treatments in high‐fat diet mouse models of non‐alcoholic fatty liver disease;The Journal of Pathology;2024-01-05